Novartis continues to be a strong player in the biotech market. Brokerages give the company a consensus rating of "Moderate Buy". The company's series of strategic acquisitions including Synnovation Therapeutics' Pan-Mutant Selective PI3KΞ± Inhibitor Program and a $3B Oncology deal for a breast cancer asset displays their aggressive growth strategy. Additionally, Novartis has also acquired Pikavation Therapeutics for $3 billion, expanded its rare disease portfolio, and completed a $12 billion purchase of Avidity Biosciences. The company's U.S. deal might protect it from potential tariffs. It is also launching a new share buyback program and made substantial progress in its investment pipeline, adding to its attractiveness for investors. Novartis shares hit all-time high and entered into a definitive agreement to raise $11 billion in the U.S. Bond Offering. Despite few hiccups, Novartis showcases robust financial health and holds significant potential to be a principal holding for long-term investors.
Novartis Stocks News Analytics from Tue, 08 Jul 2025 07:00:00 GMT to Sat, 21 Mar 2026 11:41:30 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -3
